Rocket Pharmaceuticals, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Rocket Pharmaceuticals, Inc. (RCKT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 18.48 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 18.48M shares, a 18.76% decline year-over-year.
- Rocket Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 22.75M shares.
- Rocket Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2020-09-30 was 12.56M shares, a 11.69% increase year-over-year.
- Rocket Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2020-06-30 was 12.41M shares, a 18.15% increase year-over-year.
- Rocket Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2019 was 11.38M shares, a 56.63% decline from fiscal 2018.
- Rocket Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2018 was 26.23M shares, a 0.00% change from fiscal 2017.
- Rocket Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2017 was 26.23M shares, a 63.95% increase from fiscal 2016.
- Rocket Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2016 was 16.00M shares, a 847.82% increase from fiscal 2015.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 18.48M shares 10-Q · filed 2026-08-10 | 18.23M shares 10-Q · filed 2026-08-10 | ||||||
| 2025-06-30 | 22.75M shares 10-Q · filed 2026-08-10 | 22.75M shares 10-Q · filed 2026-08-10 | ||||||
| 2020-09-30 | 12.56M shares 10-Q · filed 2020-11-06 | 12.56M shares 10-Q · filed 2020-11-06 | ||||||
| 2020-06-30 | 12.41M shares 10-Q · filed 2020-08-05 | 12.41M shares 10-Q · filed 2020-08-05 | ||||||
| 2020-03-31 | 12.17M shares 10-Q · filed 2020-05-08 | |||||||
| 2019-12-31 | 11.38M shares 10-K · filed 2020-03-06 | |||||||
| 2019-09-30 | 11.24M shares 10-Q · filed 2020-11-06 | 11.24M shares 10-Q · filed 2020-11-06 | ||||||
| 2019-06-30 | 10.51M shares 10-Q · filed 2020-08-05 | 11.07M shares 10-Q · filed 2019-08-08 | 10.51M shares 10-Q · filed 2020-08-05 | 11.07M shares 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | 11.03M shares 10-Q · filed 2020-05-08 | |||||||
| 2018-12-31 | 26.23M shares 10-K · filed 2020-03-06 | 10.25M shares 10-K · filed 2019-03-08 | ||||||
| 2018-09-30 | 10.11M shares 10-Q · filed 2019-11-08 | 10.11M shares 10-Q · filed 2019-11-08 | ||||||
| 2018-06-30 | 10.51M shares 10-Q · filed 2019-08-08 | 10.51M shares 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | 10.27M shares 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | 26.23M shares 10-K · filed 2019-03-08 | 2.43M shares 10-K · filed 2018-03-07 | ||||||
| 2017-09-30 | 26.23M shares 10-Q · filed 2018-11-09 | 9.99M shares 10-Q · filed 2017-11-08 | 26.23M shares 10-Q · filed 2018-11-09 | 9.99M shares 10-Q · filed 2017-11-08 | ||||
| 2017-06-30 | 26.27M shares 10-Q · filed 2018-08-14 | 10.44M shares 10-Q · filed 2017-08-03 | 26.27M shares 10-Q · filed 2018-08-14 | 10.44M shares 10-Q · filed 2017-08-03 | ||||
| 2017-03-31 | 25.68M shares 10-Q · filed 2018-05-11 | 10.45M shares 10-Q · filed 2017-05-10 | ||||||
| 2016-12-31 | 16.00M shares 10-K · filed 2019-03-08 | 9.69M shares 10-K · filed 2017-03-16 | ||||||
| 2016-09-30 | 9.25M shares 10-Q · filed 2017-11-08 | 9.25M shares 10-Q · filed 2017-11-08 | ||||||
| 2016-06-30 | 2.59M shares 10-Q · filed 2017-08-03 | 2.59M shares 10-Q · filed 2017-08-03 | ||||||
| 2016-03-31 | 2.46M shares 10-Q · filed 2017-05-10 | |||||||
| 2015-12-31 | 1.69M shares 10-K · filed 2017-03-16 | |||||||
| 2015-09-30 | 1.60M shares 10-Q · filed 2016-11-09 | 1.60M shares 10-Q · filed 2016-11-09 | ||||||
| 2015-06-30 | 4.78M shares 10-Q · filed 2016-08-10 | 4.78M shares 10-Q · filed 2016-08-10 | ||||||
| 2015-03-31 | 4.30M shares 10-Q · filed 2016-05-11 | |||||||
| 2014-12-31 | 8.79M shares 10-K · filed 2016-03-23 | |||||||
| 2014-09-30 | 8.83M shares 10-Q · filed 2015-11-12 | 8.83M shares 10-Q · filed 2015-11-12 | ||||||
| 2014-06-30 | 7.78M shares 10-Q · filed 2015-08-07 | 7.78M shares 10-Q · filed 2015-08-07 | ||||||
| 2014-03-31 | 7.65M shares 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |